Emmaus Life Sciences, Inc. announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older. There are around 3,000 patients with sickle cell disorders in Oman1. The birth prevalence of infants with hemoglobin disorders was 3.5-4.7 per 1,000.

Around 6% of Omanis are carriers of the gene for sickle cell anaemia. Endari® is also approved for marketing in the United States, Israel, Bahrain, Kuwait, Qatar, and the United Arab Emirates and is available on a named patient or early access basis in France, The Netherlands, and the Kingdom of Saudi Arabia. Emmaus is pursuing additional regulatory approvals for Endari® in other countries where sickle cell disease is prevalent.